Global Deferoxamine Market Insights, Forecast to 2028

Deferoxamine (DFOA), sold under the brand name Desferal, is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin
Market Analysis and Insights: Global Deferoxamine Market
Due to the COVID-19 pandemic, the global Deferoxamine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Injection for Solution accounting for % of the Deferoxamine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Aluminum Overload segment is altered to an % CAGR throughout this forecast period.
China Deferoxamine market size is valued at US$ million in 2021, while the US and Europe Deferoxamine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Deferoxamine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Deferoxamine include APP Pharmaceuticals, Hospira, Watson Laboratories, Novartis Pharmaceuticals, Fresenius Kabi, Gland Pharma, West-Ward Pharms and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Deferoxamine Scope and Segment
Deferoxamine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Deferoxamine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Injection for Solution
Powder for Solution
Lyophilized for Solution
Segment by Application
Aluminum Overload
Chronic Iron Overload
Chronic Aluminum Overload
Acute Iron Intoxication
By Company
APP Pharmaceuticals
Hospira
Watson Laboratories
Novartis Pharmaceuticals
Fresenius Kabi
Gland Pharma
West-Ward Pharms
Novartis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE